Close Menu

This article has been updated to include comments made during Bio-Rad's earnings call.

NEW YORK (GenomeWeb) – Bio-Rad Laboratories reported after the close of the market Wednesday that its second quarter revenues climbed 2 percent year over year as its profit was hit by expenses.

The Hercules, California-based life sciences tools and diagnostics firm reported total revenues of $516.8 million for the three months ended June 30 compared to $506.1 million for Q2 2015.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.